4591 Ribomic
- 82
- -2-2.38%
Ribomic News
Ribomic: Financial results briefing for the 2nd quarter (interim period) of the fiscal year ending 2025/3 (Q & A)
Ribomic: Financial results briefing materials for the 2nd quarter (interim period) of the fiscal year ending 2025/3
Volume change rate ranking (9 AM slot) - SOMPOHD, KADOKAWA, etc. are ranked.
In the volume change rate ranking, you can understand the market participants' interest in trends such as speculation by comparing the volume of the latest 5-day average with the volume on the delivery date. Top change rate in volume [As of 9:32 on November 20] (comparison of volume with the latest 5-day average) Stock code Stock name Volume 5-day average volume Volume change rate Stock price change rate <7357> Geocode 110,000 1071 85.083 2101.02% 0.072% <9468>
AHC Group, AR Advanced, and others.
A basic agreement has been concluded for a business partnership with Inventec Corporation (Taipei), which is engaged in the manufacturing and sales of electronic equipment such as notebook PCs, servers, and mobile devices, etc.
Port, Wajin, and others [Emerging Markets Press Release]
Revision downward for Curry's operating profit forecast this fiscal year from 0.49 billion yen to 0.406 billion yen. Introducing a shareholder benefit system for Information Strategy Co., Ltd. Acquired the stock of United Best Co., the holding company of Global Assist Holdings, which operates UNITED individual tutoring school, and made it a subsidiary. Revised performance forecast for THECOO, expecting an operating loss of 0.17 billion yen this fiscal year, down from 0.4 billion yen. CCT downward revision, operating profit forecast for this fiscal year is 2 billion yen, down from 2.398 billion.
Ribomic: Confirmatory letter.
Ribomic: Half Year Report - Term 22 (2024/04/01 - 2025/03/31)
Ribomic Sees Reduced Losses in Latest Financial Report
Ribomic Sees FY Loss Y1.40B
Ribomic: Summary of financial results for the 2nd quarter (interim period) of the fiscal year ending 2025/3 [Japanese GAAP] (unconsolidated)
Daiwa House, Idemitsu Kosan, Tokyo Electron Ltd. unsponsored adr, SoftBank Group (12th)
※Please note that the above calendar is subject to change depending on the company's circumstances. --------------------------------------- November 12 (Tuesday) ＜1431＞ Livework ＜146A＞ Colombia ＜148A＞ Hatchwork ＜1491＞ Chugai Mining ＜1605＞ INPEX ＜1663＞ K&O Energy ＜166A＞ Taski HD ＜1770＞ Fujita E
Stocks that moved the previous day part2 lannett co inc, Fit Easy, Cloud W, etc.
Stock names <code> 6th closing price ⇒ Significant vacuum compared to the previous day＜6962＞ 562 -52 Operating loss for the first half due to exchange rate losses. Duskin＜4665＞ 3770 -278 downward revision of performance and dividend estimates. Gree＜3632＞ 427 -38 Turning to an operating loss in the first quarter. FC Sea＜7296＞ 2694 -158 Although it rose sharply on the 5th due to a substantial increase in dividends, etc., Sus Spirits＜2222＞ 2049.5 -63.5 Feeling of exhaustion as the full-year plan remains unchanged.
The Tokyo Stock Exchange Gross Index rebounded, and after a round of buying, the increase narrowed.
TSE Growth Market Index 797.12 +4.14 / Volume 0.2 billion 43.61 million shares / Trading value 112.5 billion yen TSE Growth Market 250 Index 621.45 +3.32 / Volume 74.25 million shares / Trading value 67.8 billion yen Today's growth market, both the Growth Market Index and the Growth Market 250 Index rebounded, with 300 gainers, 233 losers, and 54 unchanged. Today's growth market has shown a firm development. Dow Jones Industrial Average from the previous 5-day US market
Emerging markets stocks digest: Cloud W surged significantly, Flutter hit a year-to-date high.
<4599> Stem Rim 366 +11 rebounds significantly after 5 days. The application patent for a peptide medicine created from the lead compound derived from HMGB1, a regenerative medicine candidate for Shionogi <4507>, has been announced to be registered in Japan. The patent secures the potential for developing a therapeutic drug for inflammatory bowel diseases (ulcerative colitis, Crohn's disease). Ledasemtide has effects such as suppressing weight loss in animal models of inflammatory bowel diseases and suppressing inflammation.
Active and newly listed stocks during the morning session.
*Enplus <6961> 5550 +550, Ichiboshi Securities upgrades its investment rating. *Itoki <7972> 1606 +146, turns to operating profit increase in the third quarter cumulative total. *Kyushu FG <7180> 778 +70.5, upward revision of performance and dividends estimates. *JMDC <4483> 4633 +368, first half exceeds previous plans. *Fujimi Incorporated <5384> 2504 +186, evaluates substantial increase in first half earnings. *Nomura Micro
Hot stocks digest (morning): Mercari, Itohki, Cloud W, etc.
ItoKoki <7972>: 1606 yen (+146 yen) surged significantly. The company announced its third quarter financial results the previous day, with cumulative operating profit reaching 7.81 billion yen, an 8.7% increase compared to the same period last year, turning from a 2.0% decrease in the first half of the year to an increase. The full-year financial estimate remains at 10 billion yen, a 17.3% increase from the previous year. Sales of the workplace business have been performing well, and it seems that cost reductions in logistics have also contributed to increased revenue. As for the third quarter cumulative performance, both revenue and operating profit have reached all-time highs.
RevoMik--Significant effectiveness confirmed in the early-phase Phase 2 clinical trial of treatment for cartilage agenesis.
Significant increase. It has been announced that in the early phase 2 clinical trial of a therapeutic drug targeting pediatric patients (5-14 years old) with cartilage imperfection syndrome, a remarkable effect (increase in growth rate) was confirmed in the low-dose subcutaneous administration group. Out of the 6 participants who completed the trial, 5 have transitioned to a long-term low-dose administration trial, continuing to evaluate the effectiveness and safety of the investigational drug. In addition, the high-dose subcutaneous administration trial has completed registration for 7 participants, with administration started in 4 participants, and the results are expected to be revealed in September next year.
Renaissance, stem inc rim, and others.
Upward revision, previous operating profit outlook 0.063 billion yen ← 0.025 billion yen.
Express News | Ribomic Inc - No Safety Concerns in Ongoing Phase Iia Clinical Trials
Express News | Ribomic Inc - Results of Cohort 2 Study Expected in September 2025
Analysis
Price Target
No Data
No Data